Trials / Completed
CompletedNCT01371838
A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 848 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 150 Years
- Healthy volunteers
- Not accepted
Summary
This purpose of this study is to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ceftaroline | Two consecutive infusions q12h for 5 to 7 days |
| DRUG | Ceftriaxone | One dose infusion followed by IV saline placebo infused q24h for 5 to 7 days plus two consecutive saline placebo infusion q24h. |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2013-05-01
- Completion
- 2013-05-01
- First posted
- 2011-06-13
- Last updated
- 2017-09-06
- Results posted
- 2014-09-23
Locations
43 sites across 5 countries: China, India, South Korea, Taiwan, Vietnam
Source: ClinicalTrials.gov record NCT01371838. Inclusion in this directory is not an endorsement.